ClinicalTrials.gov
public full text
Public Domain
A Phase 1 Clinical Trial of NTQ5082 in Healthy Volunteers
NTQ5082 capsule is a small molecule CFB factor inhibitor. The study is a randomized, double-blind, placebo-controlled, dose escalation phase 1 clinical trial to evaluate the safety, tolerability and PK/PD characteristics of NTQ5082 capsules orally administered in healthy subjects in single and multiple doses.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1#1057376
- A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)#1228624
- Administration of CBG000592 (Riboflavin/Vitamin B2) in Patients With Acute Ischemic Stroke#992748
- Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult Subjects#1114518
- N-Acetylcysteine for Patients With COPD and ChronicBronchitis#828912
Record · ID 1322515
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive